Bromocriptine versus levodopa in early Parkinson's disease

Abstract

Bromocriptine versus levodopa in early Parkinson's disease (Review)

Multi-Transcriptome-Informed Network Pharmacology Reveals Novel Biomarkers and Therapeutic Candidates for Parkinson’s Disease

“…It should be noted that all of our predicted drug molecules, Nilotinib [ 1 , 87 ], Bromocriptine [ 88 , 89 ], Withaferin-A [ 90 , 91 ], Celastrol [ 92 , 93 ], and Donepezil [ 94 , 95 ], have been validated experimentally as promising therapeutic options for PD in previous independent studies. As highlighted in the referenced article, Nilotinib has the potential to enhance dopamine metabolism, offering a therapeutic avenue for addressing both motor and nonmotor symptoms of PD.…”

Multi-Transcriptome-Informed Network Pharmacology Reveals Novel Biomarkers and Therapeutic Candidates for Parkinson’s Disease

“…It should be noted that all of our predicted drug molecules, Nilotinib [ 1 , 87 ], Bromocriptine [ 88 , 89 ], Withaferin-A [ 90 , 91 ], Celastrol [ 92 , 93 ], and Donepezil [ 94 , 95 ], have been validated experimentally as promising therapeutic options for PD in previous independent studies. As highlighted in the referenced article, Nilotinib has the potential to enhance dopamine metabolism, offering a therapeutic avenue for addressing both motor and nonmotor symptoms of PD.…”

Dopamine D2receptor signaling modulates mutant ataxin‐1 S776 phosphorylation and aggregation

“…D2R agonist BRC has been used to treat PD and may be potentially therapeutic for SCA1 patients (Calne et al. 1974; van Hilten et al. 2000).…”

Diagnosis and Treatment of Common Forms of Tremor

“…In patients younger than 60 years of age, dopamine agonists may be considered as there is some evidence for a possibly lower risk for dyskinesias in later stages of the disease, compared with when treatment was initiated with levodopa. 66 More recently, 10-year follow-up data from a multicenter cohort found no such difference. 67 Beta-blockers have a documented effect also in parkinsonian tremor, but may increase the orthostatic hypotension that often develops in PD, which can have serious consequences.…”

Multi-Transcriptome-Informed Network Pharmacology Reveals Novel Biomarkers and Therapeutic Candidates for Parkinson’s Disease

“…It should be noted that all of our predicted drug molecules, Nilotinib [ 1 , 87 ], Bromocriptine [ 88 , 89 ], Withaferin-A [ 90 , 91 ], Celastrol [ 92 , 93 ], and Donepezil [ 94 , 95 ], have been validated experimentally as promising therapeutic options for PD in previous independent studies. As highlighted in the referenced article, Nilotinib has the potential to enhance dopamine metabolism, offering a therapeutic avenue for addressing both motor and nonmotor symptoms of PD.…”

Dopamine D2receptor signaling modulates mutant ataxin‐1 S776 phosphorylation and aggregation

“…D2R agonist BRC has been used to treat PD and may be potentially therapeutic for SCA1 patients (Calne et al. 1974; van Hilten et al. 2000).…”

Diagnosis and Treatment of Common Forms of Tremor

“…In patients younger than 60 years of age, dopamine agonists may be considered as there is some evidence for a possibly lower risk for dyskinesias in later stages of the disease, compared with when treatment was initiated with levodopa. 66 More recently, 10-year follow-up data from a multicenter cohort found no such difference. 67 Beta-blockers have a documented effect also in parkinsonian tremor, but may increase the orthostatic hypotension that often develops in PD, which can have serious consequences.…”

Multi-Transcriptome-Informed Network Pharmacology Reveals Novel Biomarkers and Therapeutic Candidates for Parkinson’s Disease

“…It should be noted that all of our predicted drug molecules, Nilotinib [ 1 , 87 ], Bromocriptine [ 88 , 89 ], Withaferin-A [ 90 , 91 ], Celastrol [ 92 , 93 ], and Donepezil [ 94 , 95 ], have been validated experimentally as promising therapeutic options for PD in previous independent studies. As highlighted in the referenced article, Nilotinib has the potential to enhance dopamine metabolism, offering a therapeutic avenue for addressing both motor and nonmotor symptoms of PD.…”

Dopamine D2receptor signaling modulates mutant ataxin‐1 S776 phosphorylation and aggregation

“…D2R agonist BRC has been used to treat PD and may be potentially therapeutic for SCA1 patients (Calne et al. 1974; van Hilten et al. 2000).…”

Diagnosis and Treatment of Common Forms of Tremor

“…In patients younger than 60 years of age, dopamine agonists may be considered as there is some evidence for a possibly lower risk for dyskinesias in later stages of the disease, compared with when treatment was initiated with levodopa. 66 More recently, 10-year follow-up data from a multicenter cohort found no such difference. 67 Beta-blockers have a documented effect also in parkinsonian tremor, but may increase the orthostatic hypotension that often develops in PD, which can have serious consequences.…”